Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers

Biomedical Chromatography

Volumn 22, Issue 8, 2008, Pages 822-829

  Park, Jin Hee ^a,b   Park, Yoo Sin ^a,b   Lee, Min Ho ^a   Rhim, Si Youn ^b   Song, Jae Chul ^a   Lee, Soo Jin ^a   Kim, Jung Mogg ^a   Shaw, Leslie M ^c   Kang, Ju Seop ^a,b  

^a Hanyang University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bioequivalence study; LC MS MS; Pharmacokinetics; Topiramate

Indexed keywords

COLUMN CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN);

BIOEQUIVALENCE STUDY; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; PHARMACOKINETIC STUDIES; SIMPLE LIQUIDS; SIMPLE++; SPECTROMETRIC METHODS; TANDEM MASS SPECTROMETRIC; TOPIRAMATE;

ACETONITRILE;

ACETONITRILE; PREDNISONE; TOPIRAMATE; TRIETHYLAMINE;

ACCURACY; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG RETENTION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KOREA; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; VOLUNTEER;

EID: 50049126171     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.995     Document Type: Article

References (54)

1. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Annals of General Psychiatry 2005; 4: 5.
2. Bahrami G, Mirzaeei S and Kiani A. Sensitive analytical method for topiramate in human serum by HPLC with pre-column fluorescent derivatization and its application in human pharmacokinetic studies. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2004; 813: 175-180.
3. Bahrami G, Mirzaeei S, Mohammadi B and Kiani A. High performance liquid chromatographic determination of topiramate in human serum using UV detection. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2005; 822: 322-325.
4. Bahrami G and Mohammadi B. A novel high sensitivity HPLC assay for topiramate, using 4-chloro-7-nitrobenzofurazan as pre-column fluorescence derivatizing agent. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2007; 850: 400-404.
5. Barzman D and Delbello M. Topiramate for co-occurring bipolar disorder and disruptive behavior disorders. The American Journal of Psychiatry 2006; 163: 1451-1452.
6. Barzman D, Delbello M, Kowatch R, Warner J, Rofey D, Stanford K, Rappaport K, Daniels J and Strakowski S. Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. Journal of Child and Adolescent Psychopharmacology 2005; 15: 931-937.
7. Berry D and Patsalos P. Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. Therapeutic Drug Monitoring 2000; 22: 460-464.
8. Bialer M, Doose D, Murthy B, Curtin C, Wang S, Twyman R and Schwabe S. Pharmacokinetic interactions of topiramate. Clinical Pharmacokinetics 2004; 763
9. Bray G, Hollander P, Klein S, Kushner R, Levy B, Fitchet M and Perry B. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obesity Research 2003; 11: 722-733.
10. Britzi M, Soback S, Isoherranen N, Levy R, Perucca E, Doose D, Maryanoff B and Bialer M. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Therapeutic Drug Monitoring 2003; 25: 314-322.
11. Burton M, Shaw L, Schentag J and Evans W. Applied Pharmacokinetics and Pharmacodynamics; Principles of Therapeutic Drug Monitoring, 4th edn. LWW: Philadelphia, 2005; 8.
12. Chen S and Carvey P. Rapid approach to the quantitative determination of topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) in human plasma by liquid-liquid extraction and flow-injection negative-ion electrospray mass spectrometry. Rapid Communications in Mass Spectrometry 1999; 13: 1980-4984.
13. Chen S and Carvey P. Validation of liquid-liquid extraction followed by flow-injection negative ion electrospray mass spectrometry assay to topiramate in human plasma. Rapid Communications in Mass Spectrometry 2001; 15: 159-163.
14. Christensen J, Hojskov C and Poulsen J. Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: validation and comparison with fluorescence-polarization immunoassay. Therapeutic Drug Monitoring 2002; 24: 658-664.
15. Coppola G, Caliendo G, Veggiotti P, Romeo A, Tortorella G, De Marco P and Pascotto A. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Research 2002; 51: 147-153.
16. Correll C. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46: 687-700.
17. Doose D, Walker S, Gisclon L and Nayak R. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. Journal of Clinical Pharmacology 1996; 36: 884-891.
18. Doose D, Scott V, Cawley D, Desai D, Stenglein K, Stenury A, Walker S, Mueggler P and Stubbs R. Comparison of a fluorescence polarization immunoassay with a capillary GC/NPD assay for the antiepileptic agent topiramate in human plasma. Epilepsia 1998; 36: 48.
19. Doose D and Streeter A. Antiepileptic drugs. In Levy R, Mattson R, Meldrum B and Perucca E (eds), 5th ed. Lippincott, Williams & Wilkins: Philadelphia, USA, 2002; 727-734.
20. Edwards K, Potter D, Wu S, Kamin M and Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectrums 2003; 8: 428-432.
21. Garnett W. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41(suppl. 1): S61-65.
22. Glauser T, Levisohn P, Ritter F and Sachdeo R. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000; 41(suppl. 1): S86-90.
23. Gobbi G, Gaudreau P and Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. Journal of Clinical Psychopharmacology 2006; 26: 467-473.
24. FDA, CDER and CVM. Guidance for Industry: Bioanlytical Method Validation, 2001.
25. Halpern A. Topiramate may help reduce weight and blood pressure in obese people. Commentary. Evidence-based Cardiovascular Medicine 2005; 9: 258-260.
26. Holland M, Uetz J and Ng K. Automated capillary gas chromatographic assay using flame ionization detection for the determination of topiramate in plasma. Journal of Chromatography 1988; 433: 276-281.
27. Johannessen S, Battino D, Berry D, Bialer M, Kramer G, Tomson T and Patsalos Pn. Therapeutic drug monitoring of the newer anti-epileptic drugs. Therapeutic Drug Monitoring 2003; 25: 347-363.
28. Johnson B, Ait-Daoud N, Bowden C, Diclemente C, Roache J, Lawson K, Javors M and Ma J. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-1685.
29. Khazaal Y, Cornuz J, Bilancioni R and Zullino D. Topiramate for smoking cessation. Psychiatry and Clinical Neurosciences 2006; 60: 384-388.
30. Ko Y, Joe S, Jung I and Kim S. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clinical Neuropharmacology 2005; 28: 169-175.
31. Kotwal R, Guerdjikova A, Mcelroy S and Keck P Jr. Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity. Human Psychopharmacology 2006; 21: 425-431.
32. Lainez M, Pascual J, Pascual A, Santonja J, Ponz A and Salvador A. Topiramate in the prophylactic treatment of cluster headache. Headache 2003; 43: 784-789.
33. Langtry H, Gillis J and Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752-773.
34. Lin Y, Liu C and Hsiao M. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry and Clinical Neurosciences 2005; 59: 613-615.
35. Lung F, Liu C, Wang C and Tzeng D. Adjunctive topiramate treatment for a refractory familial adolescent mania. World Journal of Biology and Psychiatry 2007; 1-4.
36. Markind J. Topiramate: a new antiepileptic drug. American Journal of Health Systems and Pharmaceutics 1998; 55: 554-562.
37. Masucci J, Ortegon M, Jones W, Shank R and Caldwell G. In vivo microdialysis and liquid chromatography/thermospray mass spectrometry of the novel anticonvulsant 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (topiramate) in rat brain fluid. Journal of Mass Spectrometry 1998; 33: 85-88.
38. Matsuura M. Newer antiepileptic drugs. Brain and Nerve 2007; 59: 147-156.
39. McElroy S, Shapira N, Arnold L, Keck P, Rosenthal N, Wu S, Capece J, Fazzio L and Hudson J. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. The Journal of Clinical Psychiatry 2004; 65: 1463-1469.
40. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clinical Pharmacokinetics 2000; 38: 191-204.
41. Rosenfeld W. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clinical Therapeutics 1997; 19: 1294-1308.
42. Roy Chengappa K, Kupfer D, Parepally H, John V, Basu R, Buttenfield J, Schlicht P, Houck P, Brar J and Gershon S. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disorders 2007; 9: 609-617.
43. Sachdeo R. Topiramate. Clinical profile in epilepsy. Clinical Pharmacokinetics 1998; 34: 335-346.
44. Shah V, Midha K, Findlay J, Hill H, Hulse J, Mcgilveray I, Mckay G, Miller K, Patnaik R, Powell M, Tonelli A, Viswanathan C and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
45. Shargel L, Wu-Pong S and Yu A. Applied biopharmaceutics and pharmacokinetics: Bioavailability and bioequivalence, 5th ed. McGraw Hill: New York, USA, 2005; 161.
46. Tang P, Miles M, Glauser T, Coletta L, Doughman N, Doose D, Frey M and Degrauw A. An improved gas chromatography assay for topiramate monitoring in pediatric patients. Therapeutic Drug Monitoring 2000; 22: 195-201.
47. Tomson T and Johannessen S. Therapeutic monitoring of the new antiepileptic drugs. European Journal of Clinical Pharmacology 2000; 55: 697-705.
48. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A and Fitchet M. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. The American Journal of Cardiology 2005; 96: 243-251.
49. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X and Fitchet M. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. International Journal of Obesity 2007; 31: 138-146.
50. Tremblay A, Chaput J, Berube-Parent S, Prud'homme D, Leblanc C, Almeras N and Despres JP. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. European Journal of Clinical Pharmacology 2007; 63: 123-134.
51. Van Ameringen M, Mancini C, Pipe B, Campbell M and Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. The Journal of Clinical Psychiatry 2002; 63: 981-984.
52. Wilding J, Van Gaal L, Rissanen A, Vercruysse F and Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity Related Metabolic Disorders 2004; 28: 1399-1410.
53. World Medical Association. Decalration of Helsinki. Law and Medical Health Care, 1991.
54. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T. A pharmacokinetic analysis program (multi) for microcomputer. Journal of Pharmacobio-dynamics 1981; 4: 979-885.